Philip V. LoGrasso
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Philip V. LoGrasso has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
Michael D. Cameron
Medicinal Chemistry; ‡Discovery Biology; ∞Crystallography/Modeling Facility; §Drug Metabolism and Pharmacokinetics, Translational Research Institute, and ¥Department of Molecular Therapeutics, The Scripps Research Institute, Scripps Florida, 130 Scripps Way, #2A1, Jupiter, Florida 33458, United States
11 shared publicationsHaJeung Park
Medicinal Chemistry, Discovery Biology, Crystallography/Modeling Core Facility, Translational Research Institute, and Department of Molecular Therapeutics, The Scripps Research Institute , 130 Scripps Way, #2A1, Jupiter, Florida 33458, United States
8 shared publicationsLi Lin
Medicinal Chemistry; ‡Discovery Biology; ∞Crystallography/Modeling Facility; §Drug Metabolism and Pharmacokinetics, Translational Research Institute, and ¥Department of Molecular Therapeutics, The Scripps Research Institute, Scripps Florida, 130 Scripps Way, #2A1, Jupiter, Florida 33458, United States
8 shared publicationsSarah Iqbal
Department of Molecular Therapeutics and Translational Research Institute, The Scripps Research Institute, Jupiter, Florida, USA
8 shared publications- Jeremy W. Chambers
Florida International University
7 shared publications Pamela Hernandez
Medicinal Chemistry, Discovery Biology, Crystallography/Modeling Core Facility, Translational Research Institute, and Department of Molecular Therapeutics, The Scripps Research Institute , 130 Scripps Way, #2A1, Jupiter, Florida 33458, United States
7 shared publications
Latest Publications
- Open Access
- 1 June 2015
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 35 (11) , 1992-2006
Serum- and Glucocorticoid-Inducible Kinase 1 Confers Protection in Cell-Based and in In Vivo Neurotoxin Models via the c-Jun N-Terminal Kinase Signaling Pathway
Serum glucocorticoid kinase 1 (SGK1) has been shown to be protective in models of Parkinson's disease, but the details by which it confers benefit is unknown. The current study was designed to investigate the details by which SGK1 confers neuroprotection. To do this we employed a cellular neurodegeneration model to investigate JNK signaling and endoplasmic reticulum (ER) stress induced by 6-hydroxydopamine. SGK1 adenovirus was created and used to over-express SGK1 in SHSY5Y cells and dexamethasone was used to increase endogenous expression of SGK1. Oxidative stress, mitochondrial dysfunction, and cell death were monitored to test the protective effect of SGK1. To investigate the effect of SGK1 over-expression in vivo, SGK1 adenovirus was injected into the striatum of mice treated with1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, and protection of dopaminergic neurons was quantitatively assessed by tyrosine hydroxylase immunohistochemistry. SGK1 over-expression was found to decrease reactive oxygen species generation, alleviate mitochondrial dysfunction, and rescue cell death in vitro and in vivo by inactivating MKK4, JNK, and GSK3β and thereby decreasing ER and oxidative stress. These results suggest therapeutic strategies for activation of SGK1 may have the potential to be neuroprotective by deactivating the JNK and GSK3β pathways.
- 1 June 2015
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 35 (11) , 1992-2006
Open AccessSerum- and Glucocorticoid-Inducible Kinase 1 Confers Protection in Cell-Based and in In Vivo Neurotoxin Models via the c-Jun N-Terminal Kinase Signaling Pathway
Serum glucocorticoid kinase 1 (SGK1) has been shown to be protective in models of Parkinson's disease, but the details by which it confers benefit is unknown. The current study was designed to investigate the details by which SGK1 confers neuroprotection. To do this we employed a cellular neurodegeneration model to investigate JNK signaling and endoplasmic reticulum (ER) stress induced by 6-hydroxydopamine. SGK1 adenovirus was created and used to over-express SGK1 in SHSY5Y cells and dexamethasone was used to increase endogenous expression of SGK1. Oxidative stress, mitochondrial dysfunction, and cell death were monitored to test the protective effect of SGK1. To investigate the effect of SGK1 over-expression in vivo, SGK1 adenovirus was injected into the striatum of mice treated with1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, and protection of dopaminergic neurons was quantitatively assessed by tyrosine hydroxylase immunohistochemistry. SGK1 over-expression was found to decrease reactive oxygen species generation, alleviate mitochondrial dysfunction, and rescue cell death in vitro and in vivo by inactivating MKK4, JNK, and GSK3β and thereby decreasing ER and oxidative stress. These results suggest therapeutic strategies for activation of SGK1 may have the potential to be neuroprotective by deactivating the JNK and GSK3β pathways.
- 5 March 2015
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 6 (4) , 413-418
Pyridopyrimidinone Derivatives as Potent and Selective c-Jun N-Terminal Kinase (JNK) Inhibitors
A novel series of 2-aminopyridopyrimidinone based JNK (c-jun N-terminal kinase) inhibitors were discovered and developed. Structure–activity relationships (SARs) were systematically developed utilizing biochemical and cell based assays and in vitro and in vivo drug metabolism and pharmacokinetic (DMPK) studies. Through the optimization of lead compound 1, several potent and selective JNK inhibitors with high oral bioavailability were developed. Inhibitor 13 was a potent JNK3 inhibitor (IC50 = 15 nM), had high selectivity against p38 (IC50 > 10 μM), had high potency in functional cell based assays, and had high stability in human liver microsome (t1/2 = 76 min), a clean CYP-450 inhibition profile, and excellent oral bioavailability (%F = 87). Moreover, cocrystal structures of compounds 13 and 22 in JNK3 were solved at 2.0 Å. These structures elucidated the binding mode (Type-I binding) and can pave the way for further inhibitor design of this pyridopyrimidinone scaffold for JNK inhibition.
- 5 March 2015
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 6 (4) , 413-418
Pyridopyrimidinone Derivatives as Potent and Selective c-Jun N-Terminal Kinase (JNK) Inhibitors
A novel series of 2-aminopyridopyrimidinone based JNK (c-jun N-terminal kinase) inhibitors were discovered and developed. Structure–activity relationships (SARs) were systematically developed utilizing biochemical and cell based assays and in vitro and in vivo drug metabolism and pharmacokinetic (DMPK) studies. Through the optimization of lead compound 1, several potent and selective JNK inhibitors with high oral bioavailability were developed. Inhibitor 13 was a potent JNK3 inhibitor (IC50 = 15 nM), had high selectivity against p38 (IC50 > 10 μM), had high potency in functional cell based assays, and had high stability in human liver microsome (t1/2 = 76 min), a clean CYP-450 inhibition profile, and excellent oral bioavailability (%F = 87). Moreover, cocrystal structures of compounds 13 and 22 in JNK3 were solved at 2.0 Å. These structures elucidated the binding mode (Type-I binding) and can pave the way for further inhibitor design of this pyridopyrimidinone scaffold for JNK inhibition.
- Open Access
- 27 January 2015
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , srep08047-8047
Structural Basis and Biological Consequences for JNK2/3 Isoform Selective Aminopyrazoles
Three JNK isoforms, JNK1, JNK2, and JNK3 have been reported and unique biological function has been ascribed to each. It is unknown if selective inhibition of these isoforms would confer therapeutic or safety benefit. To probe JNK isoform function we designed JNK2/3 inhibitors that have >30-fold selectivity over JNK1. Utilizing site-directed mutagenesis and x-ray crystallography we identified L144 in JNK3 as a key residue for selectivity. To test whether JNK2/3 selective inhibitors protect human dopaminergic neurons against neurotoxin-induced mitochondrial dysfunction, we monitored reactive oxygen species (ROS) generation and mitochondrial membrane potential (MMP). The results showed that JNK2/3 selective inhibitors protected against 6-hydroxydopamine-induced ROS generation and MMP depolarization. These results suggest that it was possible to develop JNK2/3 selective inhibitors and that residues in hydrophobic pocket I were responsible for selectivity. Moreover, the findings also suggest that inhibition of JNK2/3 likely contributed to protecting mitochondrial function and prevented ultimate cell death.
- 27 January 2015
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , srep08047-8047
Open AccessStructural Basis and Biological Consequences for JNK2/3 Isoform Selective Aminopyrazoles
Three JNK isoforms, JNK1, JNK2, and JNK3 have been reported and unique biological function has been ascribed to each. It is unknown if selective inhibition of these isoforms would confer therapeutic or safety benefit. To probe JNK isoform function we designed JNK2/3 inhibitors that have >30-fold selectivity over JNK1. Utilizing site-directed mutagenesis and x-ray crystallography we identified L144 in JNK3 as a key residue for selectivity. To test whether JNK2/3 selective inhibitors protect human dopaminergic neurons against neurotoxin-induced mitochondrial dysfunction, we monitored reactive oxygen species (ROS) generation and mitochondrial membrane potential (MMP). The results showed that JNK2/3 selective inhibitors protected against 6-hydroxydopamine-induced ROS generation and MMP depolarization. These results suggest that it was possible to develop JNK2/3 selective inhibitors and that residues in hydrophobic pocket I were responsible for selectivity. Moreover, the findings also suggest that inhibition of JNK2/3 likely contributed to protecting mitochondrial function and prevented ultimate cell death.
- 26 January 2015
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 58 (4) , 1846-1861
Bis-aryl Urea Derivatives as Potent and Selective LIM Kinase (Limk) Inhibitors
The discovery/optimization of bis-aryl ureas as Limk inhibitors to obtain high potency and selectivity and appropriate pharmacokinetic properties through systematic SAR studies is reported. Docking studies supported the observed SAR. Optimized Limk inhibitors had high biochemical potency (IC50 < 25 nM), excellent selectivity against ROCK and JNK kinases (>400-fold), potent inhibition of cofilin phosphorylation in A7r5, PC-3, and CEM-SS T cells (IC50 < 1 μM), and good in vitro and in vivo pharmacokinetic properties. In the profiling against a panel of 61 kinases, compound 18b at 1 μM inhibited only Limk1 and STK16 with ≥80% inhibition. Compounds 18b and 18f were highly efficient in inhibiting cell-invasion/migration in PC-3 cells. In addition, compound 18w was demonstrated to be effective on reducing intraocular pressure (IOP) on rat eyes. Taken together, these data demonstrated that we had developed a novel class of bis-aryl urea derived potent and selective Limk inhibitors.
- 26 January 2015
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 58 (4) , 1846-1861
Bis-aryl Urea Derivatives as Potent and Selective LIM Kinase (Limk) Inhibitors
The discovery/optimization of bis-aryl ureas as Limk inhibitors to obtain high potency and selectivity and appropriate pharmacokinetic properties through systematic SAR studies is reported. Docking studies supported the observed SAR. Optimized Limk inhibitors had high biochemical potency (IC50 < 25 nM), excellent selectivity against ROCK and JNK kinases (>400-fold), potent inhibition of cofilin phosphorylation in A7r5, PC-3, and CEM-SS T cells (IC50 < 1 μM), and good in vitro and in vivo pharmacokinetic properties. In the profiling against a panel of 61 kinases, compound 18b at 1 μM inhibited only Limk1 and STK16 with ≥80% inhibition. Compounds 18b and 18f were highly efficient in inhibiting cell-invasion/migration in PC-3 cells. In addition, compound 18w was demonstrated to be effective on reducing intraocular pressure (IOP) on rat eyes. Taken together, these data demonstrated that we had developed a novel class of bis-aryl urea derived potent and selective Limk inhibitors.
- Open Access
- 21 November 2014
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 57 (23) , 10013-10030
Design and Synthesis of Highly Potent and Isoform Selective JNK3 Inhibitors: SAR Studies on Aminopyrazole Derivatives
The c-jun N-terminal kinase 3 (JNK3) is expressed primarily in the brain. Numerous reports have shown that inhibition of JNK3 is a promising strategy for treatment of neurodegeneration. The optimization of aminopyrazole-based JNK3 inhibitors with improved potency, isoform selectivity, and pharmacological properties by structure–activity relationship (SAR) studies utilizing biochemical and cell-based assays, and structure-based drug design is reported. These inhibitors had high selectivity over JNK1 and p38α, minimal cytotoxicity, potent inhibition of 6-OHDA-induced mitochondrial membrane potential dissipation and ROS generation, and good drug metabolism and pharmacokinetic (DMPK) properties for iv dosing. 26n was profiled against 464 kinases and was found to be highly selective hitting only seven kinases with >80% inhibition at 10 μM. Moreover, 26n showed good solubility, good brain penetration, and good DMPK properties. Finally, the crystal structure of 26k in complex with JNK3 was solved at 1.8 Å to explore the binding mode of aminopyrazole based JNK3 inhibitors.
- 21 November 2014
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 57 (23) , 10013-10030
Open AccessDesign and Synthesis of Highly Potent and Isoform Selective JNK3 Inhibitors: SAR Studies on Aminopyrazole Derivatives
The c-jun N-terminal kinase 3 (JNK3) is expressed primarily in the brain. Numerous reports have shown that inhibition of JNK3 is a promising strategy for treatment of neurodegeneration. The optimization of aminopyrazole-based JNK3 inhibitors with improved potency, isoform selectivity, and pharmacological properties by structure–activity relationship (SAR) studies utilizing biochemical and cell-based assays, and structure-based drug design is reported. These inhibitors had high selectivity over JNK1 and p38α, minimal cytotoxicity, potent inhibition of 6-OHDA-induced mitochondrial membrane potential dissipation and ROS generation, and good drug metabolism and pharmacokinetic (DMPK) properties for iv dosing. 26n was profiled against 464 kinases and was found to be highly selective hitting only seven kinases with >80% inhibition at 10 μM. Moreover, 26n showed good solubility, good brain penetration, and good DMPK properties. Finally, the crystal structure of 26k in complex with JNK3 was solved at 1.8 Å to explore the binding mode of aminopyrazole based JNK3 inhibitors.
- Open Access
- 10 June 2013
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 8 (8) , 1747-1754
A Small Molecule Bidentate-Binding Dual Inhibitor Probe of the LRRK2 and JNK Kinases
- 10 June 2013
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 8 (8) , 1747-1754
Open AccessA Small Molecule Bidentate-Binding Dual Inhibitor Probe of the LRRK2 and JNK Kinases
- 25 April 2013
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 56 (9) , 3568-3581
Synthesis and Biological Evaluation of Urea Derivatives as Highly Potent and Selective Rho Kinase Inhibitors
RhoA and its downstream effector ROCK mediate stress fiber formation and cell contraction through their effects on the phosphorylation of myosin light chain (MLC). Inhibition of the RhoA/ROCK pathway has proven to be a promising strategy for several indications such as cardiovascular disease, glaucoma, and inflammatory disease. In 2010, our group reported urea-based ROCK inhibitors as potential antiglaucoma agents. These compounds showed potent IC50 values in enzymatic and cell-based assays and significant intraocular pressure (IOP)-lowering effects in rats (∼7 mmHg).(22) To develop more advanced ROCK inhibitors targeting various potential applications (such as myocardial infarction, erectile dysfunction, multiple sclerosis, etc.) in addition to glaucoma, a thorough SAR for this urea-based scaffold was studied. The detailed optimization process, counter-screening, and in vitro and in vivo DMPK studies are discussed. Potent and selective ROCK inhibitors with various in vivo pharmacokinetic properties were discovered.
- 25 April 2013
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 56 (9) , 3568-3581
Synthesis and Biological Evaluation of Urea Derivatives as Highly Potent and Selective Rho Kinase Inhibitors
RhoA and its downstream effector ROCK mediate stress fiber formation and cell contraction through their effects on the phosphorylation of myosin light chain (MLC). Inhibition of the RhoA/ROCK pathway has proven to be a promising strategy for several indications such as cardiovascular disease, glaucoma, and inflammatory disease. In 2010, our group reported urea-based ROCK inhibitors as potential antiglaucoma agents. These compounds showed potent IC50 values in enzymatic and cell-based assays and significant intraocular pressure (IOP)-lowering effects in rats (∼7 mmHg).(22) To develop more advanced ROCK inhibitors targeting various potential applications (such as myocardial infarction, erectile dysfunction, multiple sclerosis, etc.) in addition to glaucoma, a thorough SAR for this urea-based scaffold was studied. The detailed optimization process, counter-screening, and in vitro and in vivo DMPK studies are discussed. Potent and selective ROCK inhibitors with various in vivo pharmacokinetic properties were discovered.
- 2 April 2013
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 52 (18) , 4800-4804
Synthesis of Benzoquinone Ansamycin‐Inspired Macrocyclic Lactams from Shikimic Acid
- 2 April 2013
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 52 (18) , 4800-4804
Synthesis of Benzoquinone Ansamycin‐Inspired Macrocyclic Lactams from Shikimic Acid
- 2 April 2013
- Published by Wiley in Angewandte Chemie
- Vol. 125 (18) , 4900-4904
Synthesis of Benzoquinone Ansamycin-Inspired Macrocyclic Lactams from Shikimic Acid
- 2 April 2013
- Published by Wiley in Angewandte Chemie
- Vol. 125 (18) , 4900-4904
Synthesis of Benzoquinone Ansamycin-Inspired Macrocyclic Lactams from Shikimic Acid
- Open Access
- 1 February 2013
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 288 (6) , 4000-4011
Inhibition of JNK Mitochondrial Localization and Signaling Is Protective against Ischemia/Reperfusion Injury in Rats
- 1 February 2013
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 288 (6) , 4000-4011
Open AccessInhibition of JNK Mitochondrial Localization and Signaling Is Protective against Ischemia/Reperfusion Injury in Rats